无创影像学定位胰岛素瘤的诊断效能:一项Meta分析
该Meta分析纳入19项研究共708例胰岛素瘤患者,评估PET/CT、SPECT/CT、CT和MRI定位胰岛素瘤的诊断效能。结果显示PET/CT的汇总敏感度0.79、特异度0.84,优于SPECT/CT、CT和MRI;基于GLP-1R的PET/CT诊断表现优于基于SSTR的PET/CT。
要点
- PET/CT定位胰岛素瘤的汇总敏感度0.79、特异度0.84,优于SPECT/CT、CT和MRI。
- 基于GLP-1R的PET/CT诊断表现优于基于SSTR的PET/CT。
- CT和MRI的汇总敏感度均为0.54,特异度分别为0.75和0.65。
核心结论
- PET/CT定位胰岛素瘤的诊断表现优于SPECT/CT、CT和MRI。
- 基于GLP-1R的PET/CT诊断表现优于基于SSTR的PET/CT。
研究设计与样本
- 系统检索PubMed、Embase、Cochrane Library、万方和中国知网,截至2021年5月31日。
- 纳入19项研究,共708例胰岛素瘤患者。
- 计算汇总敏感度、特异度、阳性似然比、阴性似然比、诊断比值比和符合率。
诊断标准与关键数值
- PET/CT汇总敏感度0.79(95% CI: 0.54-0.92),特异度0.84(95% CI: 0.20-0.99)。
- SPECT/CT汇总敏感度0.77(95% CI: 0.46-0.93),特异度0.45(95% CI: 0.22-0.70)。
- CT汇总敏感度0.54(95% CI: 0.35-0.72),特异度0.75(95% CI: 0.54-0.88)。
- MRI汇总敏感度0.54(95% CI: 0.31-0.75),特异度0.65(95% CI: 0.39-0.84)。
- PET、SPECT、CT和MRI的符合率分别为78%(95% CI: 66-90%)、74%(95% CI: 52-97%)、56%(95% CI: 41-72%)和53%(95% CI: 33-73%)。
临床应用与阅片要点
- 在胰岛素瘤定位中,可优先考虑PET/CT,尤其是基于GLP-1R的PET/CT。
- CT和MRI的敏感度较低,阴性结果不能排除胰岛素瘤。
局限性
- 原始研究之间可能存在异质性。
- 部分汇总结果置信区间宽,提示研究间变异较大或样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Insulinoma is the most common functional neuroendocrine tumor found only in the pancreas. The early detection of insulinoma is of importance. Studies comparing the performance of noninvasive modalities were limited by sample size and heterogeneity between studies. The aim of this meta-analysis was to evaluate the diagnostic performance of PET/CT, SPECT/CT, CT and MRI for the localization of insulinoma, and to provide evidence for clinical practice.
METHODS: PubMed, Embase, Cochrane Library, Wanfang Data and China National Knowledge Infrastructure were searched from inception to May 31, 2021. Pooled sensitivity, specificity, positive Likelihood Ratio (+LR) and negative Likelihood Ratio (-LR), diagnostic odds ratio (DOR), and concordance rate were calculated.
RESULTS: A total of 19 studies including 708 patients of insulinoma reached the inclusion criteria. PET/CT imaging demonstrated a pooled sensitivity of 0.79 (95% CI: 0.54-0.92) and a pooled specificity of 0.84 (95% CI: 0.20-0.99). The pooled sensitivity and specificity of SPECT/CT were 0.77 (95% CI: 0.46-0.93) and 0.45 (95% CI: 0.22-0.70). CT showed an overall sensitivity of 0.54 (95% CI: 0.35-0.72) and specificity of 0.75 (95% CI: 0.54-0.88). The pooled sensitivity and specificity for MRI were 0.54 (95% CI: 0.31-0.75) and 0.65 (95% CI: 0.39-0.84), respectively. The concordance rates of PET, SPECT, CT, and MRI were 78% (95% CI: 66-90%), 74% (95% CI: 52-97%), 56% (95% CI: 41-72%), and 53% (95% CI: 33-73%), respectively.
CONCLUSION: Results of this study indicate that PET/CT demonstrated superior performance than SPECT/CT, CT and MRI for the localization of insulinoma. GLP-1R based PET/CT manifested better diagnostic performance in comparison with SSTR based PET/CT imaging modality.
引用
- Yang, Shi, Zhu, et al. Diagnostic performance of noninvasive imaging modalities for localization of insulinoma: A meta-analysis. Eur J Radiol. 2021. PMID: 34763145. doi:10.1016/j.ejrad.2021.110016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。